Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)

Abstract

Results: A total of 441 patients were entered in a randomized study. Response rates were 30% for AC, 41% for D, and 35% for AC-D. The median times to treatment failure (TTFs) were 6.4, 6.4, and 6.7 months (one-sided log-rank test, P = 0.13 for AC versus D, P = 0.14 for AC versus AC-D) and median overall survival (OS) was 22.6, 25.7, and 25.0 months (P = 0.09 for AC versus D, P = 0.13 for AC versus AC-D) in the AC, D, and AC-D, respectively. Conclusion:There was no difference in the TTF among the three arms. However, there was a trend toward a better response and better OS in the D than in the AC.

A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer

“…Thus, TTF does not greatly affect the schedule, and it is available for use as a variable in the real-world clinical settings. In the present study, BP regimen yielded a median TTF of 6.2 months a value that is close to the median TTFs (6.6 and 8.9 months, respectively) which were described in two previous clinical studies in patients with MBC 15,16 .…”

Will Dna Methylation Inhibitors Work In Solid Tumors? A Review Of The Clinical Experience With Azacitidine And Decitabine In Solid Tumors

“…The MDS response rate of 23% is only slightly higher and comparable to the response rate in breast cancer at 18%. For further comparison, an objective response rate of 40% in metastatic breast cancer treated with docetaxel has been reported [48]. Also, first-line therapy of metastatic colorectal cancer, the oxaliplatin, infusional fluorour acil and leucovorin (FOLFOX) regimen has been reported as having statistically significant response rates as high as 45% [49].…”

The Transition of Breast Cancer Treatment and Japan Clinical Oncology Group Research Over Two Decades

“…There was no difference in TTF among the three groups. The researchers concluded that there was a favorable trend in OS for single-agent docetaxel compared with AC in this setting (15).…”

“…In the JCOG 9802 trial (Tables 2 and 3), AC, single-agent docetaxel and alternating AC and docetaxel (AC-D) were compared as first-line chemotherapy in MBC (15). Patients with MBC resistant to endocrine therapy were enrolled in the randomized study to receive either six 3-week cycles of AC (doxorubicin 40 mg/m 2 þ cyclophosphamide 500 mg/ m 2 ), docetaxel (60 mg/m 2 ) or alternating treatment with AC-D (three cycles of AC and three cycles of docetaxel).…”